Literature DB >> 10207504

Differences in reproducibility and peak growth hormone responses to repeated testing with various stimulators in healthy adults.

H C Hoeck1, P E Jakobsen, P Vestergaard, J Falhof, P Laurberg.   

Abstract

In healthy adults, GH responses to provocative testing are variable between subjects. Information on the intra-subject variability is limited, despite the importance attached to GH stimulation tests in the diagnosis of GH deficiency. We have investigated and compared the variability of different GH stimulation tests in a group of healthy control subjects. In 16 healthy non-obese adults, two insulin tolerance tests (ITT) (0.15 IU/kg body weight i.v. and a fall in blood glucose < or = 2.2 mmol/l) two GHRH tests (1 microgram/kg body weight i.v.), and two clonidine (CLO) (300 micrograms p.o.) + GHRH (60 min later) tests were performed in the morning after an overnight fast. A pyridostigmine (PD) (120 mg p.o. 60 min before GHRH) + GHRH test was performed twice in an extended group of 31 healthy adult subjects. A wide range of GH responses was observed. Both during the ITT and the GHRH test, low values in the range generally recognized to reflect impairment of GH secretory status were encountered. The median (range) peak GH responses in tests 1 and 2 were: (a) ITT: 14.4 micrograms/l (4.1-71.1) and 14.0 micrograms/l (0.09-69.5), (b) GHRH test: 21.7 micrograms/l (0.71-56.2) and 18.4 micrograms/l (1.6-55.1); (c) CLO + GHRH test: 57.4 micrograms/l (22.9-209) and 65.8 micrograms/l (12.2-206); (d) PD + GHRH test: 36.5 micrograms/l (9.1-125) and 44.6 micrograms/l (6.3-101). The coefficients of variation (CV) were: 58% (ITT), 45% (GHRH), 46% (CLO + GHRH) and 26% (PD + GHRH). The peak GH responses were significantly different in all tests (CLO + GHRH > PD + GHRH > GHRH > ITT). In the individual subject, there was no systematic correlation between the peak GH responses in the different stimulation tests. In conclusion, we found that the stimulated GH responses were highly variable in all tests, and that the peak GH responses differed. Test results in patients should be evaluated against test-specific reference values, and caution is justified in the interpretation of low responses in a single test.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10207504     DOI: 10.1054/ghir.1998.0085

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  6 in total

1.  The decreased growth hormone response to growth hormone releasing hormone in obesity is associated to cardiometabolic risk factors.

Authors:  Fernando Cordido; Jesús Garcia-Buela; Susana Sangiao-Alvarellos; Teresa Martinez; Ovidio Vidal
Journal:  Mediators Inflamm       Date:  2010-01-21       Impact factor: 4.711

Review 2.  [Pituitary and adrenal gland surgery].

Authors:  F Flohr; J Seufert
Journal:  Internist (Berl)       Date:  2007-06       Impact factor: 0.743

3.  Effect of recombinant human growth hormone on liver fat content in young adults with nonalcoholic fatty liver disease.

Authors:  Chelsea S Pan; Julian J Weiss; Lindsay T Fourman; Colleen Buckless; Karen L Branch; Hang Lee; Martin Torriani; Madhusmita Misra; Takara L Stanley
Journal:  Clin Endocrinol (Oxf)       Date:  2020-10-10       Impact factor: 3.523

4.  Prevalence of hypothalamo pituitary dysfunction in patients of traumatic brain injury.

Authors:  K V S Hari Kumar; M N Swamy; M A Khan
Journal:  Indian J Endocrinol Metab       Date:  2016 Nov-Dec

5.  Growth Hormone (GH) Therapy During the Transition Period: Should We Think About Early Retesting in Patients with Idiopathic and Isolated GH Deficiency?

Authors:  Laura Penta; Marta Cofini; Laura Lucchetti; Letizia Zenzeri; Alberto Leonardi; Lucia Lanciotti; Daniela Galeazzi; Alberto Verrotti; Susanna Esposito
Journal:  Int J Environ Res Public Health       Date:  2019-01-23       Impact factor: 3.390

6.  Hypopituitarism in Traumatic Brain Injury-A Critical Note.

Authors:  Marianne Klose; Ulla Feldt-Rasmussen
Journal:  J Clin Med       Date:  2015-07-14       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.